Assessment of soluble angiogenic markers in pancreatic cancer

Biomarkers in Medicine

Volumn 2, Issue 5, 2008, Pages 447-455

  Pistol Tanase, Cristiana ^a   Raducan, Elena ^a   Dima, Simona Olimpia ^b   Albulescu, Lucian ^a   Alina, Ionita ^a   Marius, Poroschianu ^a   Cruceru, Linda Maria ^c   Codorean, Eleonora ^a   Neagu, Teodora Monica ^a   Popescu, Irinel ^b  

^a VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^b FUNDENI CLINICAL INSTITUTE   (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Angiogenesis; bFGF; Ki67; Pancreatic cancer; Soluble angiogenic biomarkers; VEGF

Indexed keywords

ANGIOGENIC PROTEIN; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; VASCULOTROPIN;

ADULT; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PANCREAS CANCER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; TUMOR VOLUME;

EID: 59949091318     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.2.5.447     Document Type: Article

References (39)

1. Sarkar FH, Banerjee S, Li Y: Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol. Appl. Pharmacol. 224(3), 326-336 (2006).
2. Korc M: Pathways for aberrant angiogenesis in pancreatic cancer. Mol. Cancer. 7, 2-8 (2003).
3. Tassi E, Wellstein A: The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma. Semin. Oncol. 33(6 Suppl. 11), S50-S56 (2006).
4. Summy JM, Trevino JG, Baker CH et al.: c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas 31(3), 263-274 (2005).
5. Cho K, Ishiwata T, Uchida E et al.: Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer. Am. J. Pathol. 170(6), 1964-1974 (2007).
6. Ischenko I, Guba M, Yezhelyev M et al.: Effect of Src inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis 10(3), 167-182 (2007).
7. Tabernero J: The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res. 5(3), 203-220 (2007).
8. Mohammadi M, Olsen SK, Ibrahimi OA et al.: Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 16(2), 107-137 (2005).
9. Schuch G, Kisker O, Atala A et al.: Pancreatic tumor growth is regulated by the balance between positive and negative modulators of angiogenesis. Angiogenesis 5(3), 181-190 (2002).
10. Baker C, Carmen C, Solorzano et al.: Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signalling for therapy of metastatic human pancreatic cancer. Cancer Res. 62, 1996-2003 (2002).
11. Seo, Y, Baba H, Fukuda T, Takashima M, Sugimachi K: High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinorna. Cancer 88(10), 2239-2245 (2000).
12. Niedergethmann M, Hildenbrand R, Wostbrock B et al.: High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25(2), 122-129 (2002).
13. Itakura J, Ishiwata T, Shen B, Kommann M, Korc M: Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. Cancer 85(1), 27-34 (2000).
14. Karayiannakis AJ, Bolanaki H, Syrigos KN et al.: Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett. 194(1) 119-124 (2003).
15. Kobayashi A, Yamaguchi T Ishihara T et al.: Usefulness of plasma vascular endothelial growth factor in the diagnosis of pancreatic carcinoma: differential diagnosis, tumor progression, and patient survival. Pancreas 31(1), 74-78 (2005).
16. Bellone G, Novarino A, Chiappino, I et al.: Circulating vascular endothelial growth factor and interferon-γ-inducible protein- 10 levels in pancreatic during chemotherapy. Anticancer Res. 25(5), 3287-3291 (2005).
17. Li X, Feng GS, Zheng CS et al.: Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J. Gastroenterol. 10(19), 2878-2882 (2004).
18. Poon RT, Lau C, Pang R et al.: High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann. Surg. Oncol. 14(6), 1835-1845 (2007).
19. McMeekin DS, Sill MW, Benbrook D et al.: A Phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a gynecologic oncology group study. Gynecol. Oncol. 105(2), 508-516 (2007).
20. Drevs J, Zirrgiebel U, Schmidt-Gersbach CIM et al.: Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two Phase I trials. Ann. Oncol. 16, 558-565 (2005).
21. Krejci P, Dvorakova D, Krahulcova E et a.: FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias. Leukemia 15, 228-237 (2001).
22. Elshal MF, McCoy JP: Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 38 (4), 317-323 (2006).
23. Chen R, Pan S, Brentnall TA et al.: Proteomic profiling of pancreatic cancer for biomarker discovery. Mol. Cell. Proteomics 4(4), 523-533 (2005).
24. Liao Q, Zhao YP, Yang YC: Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat. Dis. Int. 6(6), 641-645 (2007).
25. Misek DE, Patwa TH, Lohman DM et al.: Early detection and biomarkers in pancreatic cancer. J Natl Compr. Canc. Netw. 5(10), 1034-1041 (2007).
26. Pistol-Tanase C: Caveolin-1: a marker for pancreatic cancer diagnosis. Expert Rev. Mol. Diagn. 8(4), 395-404 (2008).
27. Fujioka S, Yoshida K, Yanagisawa S et al.: Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. Cancer 92(7), 1788-1797 (2001).
28. Kuwahara K, Sasaki T, Kuwada Y et al.: Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. Pancreas 26 (4), 344-349 (2003).
29. Chung G, Yoon H, Zerkowski P et al.: Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in pancreatic cancer tissue microarray. Cancer 106(8), 1677-1684 (2005).
30. Cooper BC, Ritchie JM, Broghammer CL et al.: Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin. Cancer Res. 8 (10), 3193-3197 (2002).
31. Kurschat P, Eming S, Nashan D et al.: Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression. Br. J. Dermatol. 156(4), 653-658 (2007).
32. Denizot Y, De Armas R, Caire F et al.: The Quantitative analysis of bFGF and VEGF by ELISA in human meningiomas. Mediators Inflamm. 6, 36376 (2006).
33. Smolej L, Andrýs C, Krejsek J et al.: Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment. Vnitr. Lek. 53 (11), 1171-1176 (2007).
34. Dudek AZ, Mahaseth H: Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest. 23(3), 193-200, (2005).
35. Pavel ME, Hassler G, Baum U et al.: Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. Clin. Endocrinol. (Oxf.) 62(4), 434-443 (2005).
36. Fredriksson S, Horecka J, Brustugun OT et a.: Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic, and ovarian cancer. Clin. Chem. 54(3), 582-589 (2008).
37. Lash GE, Scaife PJ, Ianes BA et al.: Comparison of three multiplex cytokine analysis systems: Luminex, SearchLight and FAST Quant. J. Immunol. Methods 309(1-2), 205-208 (2006).
38. Young SH, Antonini JM, Roberts JR et al.: Performance evaluation of cytometric bead assays for the measurement of lung cytokines in two rodent models. J. Immunol. Methods 331(1-2), 59-68 (2008).
39. Saif MW: Anti-angiogenesis therapy in pancreatic carctnoma. JOP7(2), 163-173 (2006).